Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 15, 2022 07:30 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Q3 2022 FastPack ® sales increased approximately 25% year-over-yearCompany continues to execute on and advance core therapeutic programs CARLSBAD, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Qualigen...
October 19, 2022 09:00 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute

Fourth RAS Initiative Symposium Highlights Preclinical Data in Solid Tumor Models CARLSBAD, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified...
October 18, 2022 09:00 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics to Present at LD Micro Main Event XV

CARLSBAD, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
October 06, 2022 08:00 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics to Present Two Posters at the National Cancer Institute Fourth RAS Initiative Symposium

CARLSBAD, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
September 14, 2022 17:02 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Presents Data on QN-302 at AACR’s Pancreatic Cancer Meeting

Posters include data regarding 1) mode of action, and 2) preclinical toxicology CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified...
August 18, 2022 09:15 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board

CARLSBAD, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
August 16, 2022 07:30 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Q2 2022 FastPack ® Sales increased approximately 28%, and gross profit on product sales was up 64% year-over-year from Q2 2021 Milestone achievements in QN-302 and QN-247 oncology therapeutic...
August 01, 2022 08:30 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model

CARLSBAD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
July 06, 2022 09:00 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies for QN-302

CARLSBAD, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
June 14, 2022 09:00 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics to Present at BIO International Convention

CARLSBAD, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...